CO5631438A2 - Profarmacos de aminoacidos excitadores - Google Patents
Profarmacos de aminoacidos excitadoresInfo
- Publication number
- CO5631438A2 CO5631438A2 CO04122695A CO04122695A CO5631438A2 CO 5631438 A2 CO5631438 A2 CO 5631438A2 CO 04122695 A CO04122695 A CO 04122695A CO 04122695 A CO04122695 A CO 04122695A CO 5631438 A2 CO5631438 A2 CO 5631438A2
- Authority
- CO
- Colombia
- Prior art keywords
- group
- aromatic
- optionally substituted
- hydrogen
- fluoro
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
- C07C237/12—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/78—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/14—All rings being cycloaliphatic
- C07C2602/18—All rings being cycloaliphatic the ring system containing six carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychology (AREA)
- Virology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- AIDS & HIV (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
Abstract
1.- Un compuesto de Fórmula I en la que:A es H-(Q)p-;Q se selecciona independientemente, cada vez que aparece, del grupo aminoacilo;p es un número entero de 1 a 10;X es O, S, SO, SO2 o CR3R4;R3 es fluoro, XAND#39OR5, SO3H, tetrazol-5-ilo, CN, PO3R62, hidroxi, NO2, N3, (CH2)mCOOR5a, (CH2)mPO3R6a2, NHCONHR5b o NHSO2R5c y R4 es hidrógeno; o cada uno de R3 y R4 representa fluoro; o R3 y R4 representan juntos =O, =NOR7, =CR8R9, =CHCOOR5b, =CHPO3R6a2 o =CHCN; o uno de R3 o R4 representa amino y el otro representa carboxilo;XAND#39 representa un enlace, CH2 o CO;m es un número entero de 1 a 3; R5, R5a, R5b, R5c, R7, R8 y R9 son independientemente un átomo de hidrógeno; un grupo alquilo (1-6C) opcionalmente sustituido; un grupo alquenilo (2-6C) opcionalmente sustituido; un grupo alquinilo (2-6C) opcionalmente sustituido; un grupo aromático opcionalmente sustituido; un grupo heteroaromático opcionalmente sustituido; un grupo carbocíclico no aromático; un grupo heterocíclico no aromático; un grupo carbocíclico monocíclico no aromático condensado con uno o dos grupos aromáticos o heteroaromáticos monocíclicos; o un grupo heterocíclico monocíclico no aromático condensado con uno o dos grupos aromáticos o heteroaromáticos monocíclicos;R6 y R6a representan independientemente hidrógeno o un grupo alquilo (1-6C);R10 es hidrógeno o fluoro; y R11 es hidrógeno, fluoro, o hidroxi;o una de sus sales farmacéuticamente aceptables.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02380120 | 2002-06-11 | ||
EP02380121 | 2002-06-11 | ||
US41593602P | 2002-10-03 | 2002-10-03 | |
US41593702P | 2002-10-03 | 2002-10-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO5631438A2 true CO5631438A2 (es) | 2006-04-28 |
Family
ID=29740902
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO04122695A CO5631438A2 (es) | 2002-06-11 | 2004-12-07 | Profarmacos de aminoacidos excitadores |
Country Status (30)
Country | Link |
---|---|
US (5) | US7371872B2 (es) |
EP (2) | EP1897550A3 (es) |
JP (2) | JP4342437B2 (es) |
KR (1) | KR20080058509A (es) |
AR (1) | AR040257A1 (es) |
AT (1) | ATE421526T1 (es) |
AU (1) | AU2003232146B2 (es) |
BR (1) | BR0311558A (es) |
CA (1) | CA2488167C (es) |
CO (1) | CO5631438A2 (es) |
CR (2) | CR7616A (es) |
CY (1) | CY1108976T1 (es) |
DE (1) | DE60325968D1 (es) |
DK (1) | DK1517915T3 (es) |
EA (2) | EA011231B1 (es) |
EC (1) | ECSP085481A (es) |
ES (1) | ES2319116T3 (es) |
HK (1) | HK1075259A1 (es) |
HR (2) | HRP20041179B1 (es) |
IL (2) | IL165100A0 (es) |
MX (1) | MXPA04012518A (es) |
MY (1) | MY146238A (es) |
NO (2) | NO331780B1 (es) |
NZ (3) | NZ536459A (es) |
PE (1) | PE20040555A1 (es) |
PL (1) | PL221489B1 (es) |
PT (1) | PT1517915E (es) |
SI (1) | SI1517915T1 (es) |
WO (1) | WO2003104217A2 (es) |
ZA (1) | ZA200409553B (es) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ536459A (en) * | 2002-06-11 | 2008-03-28 | Lilly Co Eli | Prodrugs of excitatory amino acids |
AR059898A1 (es) | 2006-03-15 | 2008-05-07 | Janssen Pharmaceutica Nv | Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2 |
TW200845978A (en) | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
MY152078A (en) | 2007-09-14 | 2014-08-15 | Ortho Mcneil Janssen Pharm | 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h,1'h-[1,4']bipyridinyl-2'-ones |
US8691849B2 (en) | 2008-09-02 | 2014-04-08 | Janssen Pharmaceuticals, Inc. | 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors |
JP5656848B2 (ja) | 2008-10-16 | 2015-01-21 | ジャンセン ファーマシューティカルズ, インコーポレイテッド. | 代謝型グルタミン酸受容体モジュレーターとしてのインドールおよびベンゾモルホリンの誘導体 |
RU2512283C2 (ru) | 2008-11-28 | 2014-04-10 | Янссен Фармасьютикалз, Инк. | Производные индола и бензоксазина в качестве модуляторов метаботропных глутаматных рецепторов |
WO2010111080A2 (en) | 2009-03-27 | 2010-09-30 | Eli Lilly And Company | Optimized treatment of schizophrenia |
PT2430022E (pt) | 2009-05-12 | 2013-12-26 | Janssen Pharmaceuticals Inc | Derivados de 1,2,3-triazolo[4,3-a]piridina e a sua utilização para o tratamento ou prevenção de doenças neurológicas e psiquiátricas |
EA020671B1 (ru) | 2009-05-12 | 2014-12-30 | Янссен Фармасьютикалз, Инк. | ПРОИЗВОДНЫЕ 1,2,4-ТРИАЗОЛО[4,3-a]ПИРИДИНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ПОЛОЖИТЕЛЬНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ РЕЦЕПТОРОВ mGluR2 |
MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
KR102099692B1 (ko) * | 2009-06-29 | 2020-04-10 | 인올렉스 인베스트먼트 코포레이션 | 비 석유화학적으로 유도된 중성화된 아미노산 에스테르로 이루어진 양이온 유화제 및 그와 관련된 조성물과 방법들 |
JO2978B1 (en) | 2009-12-21 | 2016-03-15 | ايلي ليلي اند كومباني | MGLU2 aids |
US8993591B2 (en) | 2010-11-08 | 2015-03-31 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors |
ES2552455T3 (es) | 2010-11-08 | 2015-11-30 | Janssen Pharmaceuticals, Inc. | Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2 |
US9012448B2 (en) | 2010-11-08 | 2015-04-21 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors |
KR101554793B1 (ko) * | 2010-11-18 | 2015-09-21 | 일라이 릴리 앤드 캄파니 | mGluR 2/3 길항제로서의 4-치환된-3-벤질옥시-비시클로[3.1.0]헥산 화합물 |
AR083845A1 (es) * | 2010-11-18 | 2013-03-27 | Lilly Co Eli | COMPUESTOS 3-FENILSULFANILMETIL-BICICLO[3.1.0]HEXANO 4-SUSTITUIDOS COMO ANTAGONISTAS DE mGluR2/3 |
RS54888B1 (sr) | 2011-06-17 | 2016-10-31 | Lilly Co Eli | Derivati biciklo(3.1.0)heksan-2,6-dikarboksilne kiseline kao agonisti mglu2 receptora |
AR089718A1 (es) * | 2012-02-01 | 2014-09-10 | Lilly Co Eli | AGONISTAS DE mGlu2/3 |
MX355161B (es) | 2012-06-01 | 2018-04-06 | Taisho Pharmaceutical Co Ltd | Profarmaco de aminoacido que contiene fluor. |
JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
JO3367B1 (ar) * | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2 |
WO2015110435A1 (en) * | 2014-01-21 | 2015-07-30 | Janssen Pharmaceutica Nv | Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use |
ME03518B (me) | 2014-01-21 | 2020-04-20 | Janssen Pharmaceutica Nv | Kombinacije koje obuhvataju pozitivne alosterične modulatore ili ortosterične agoniste metabotropnog glutamatergičnog receptora podtipa 2 i njihova primjena |
CN105985389B (zh) * | 2015-03-06 | 2019-03-19 | 北京大学 | 苯乙醇苷类似物及其合成方法和应用 |
JP6801835B2 (ja) | 2015-07-09 | 2020-12-16 | ミメトゲン ファーマシュウティカルズ インコーポレイテッドMimetogen Pharmaceuticals, Inc. | β−ターンペプチド模倣環状塩の液相合成及び結晶化 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US200488A (en) | 1878-02-19 | Improvement in temporary binders | ||
US1459765A (en) * | 1922-03-18 | 1923-06-26 | Wordsworth M Elliott | Interchangeable sign letters |
WO1993006127A1 (en) * | 1991-09-17 | 1993-04-01 | Warner-Lambert Company | Novel amino acid prodrug renin inhibitors |
US5849525A (en) | 1994-03-09 | 1998-12-15 | Brigham And Women's Hospital, Inc. | Compositions corresponding to a proton-coupled peptide transporter and methods of making and using same |
EP0732781B1 (fr) * | 1995-03-14 | 2002-12-18 | Brown & Sharpe Tesa S.A. | Module comprenant une diode laser asservie et dispositif électro-optique muni d'un tel module |
ZA969486B (en) * | 1995-11-16 | 1998-05-12 | Lilly Co Eli | Excitatory amino acid derivatives. |
US5688826A (en) * | 1995-11-16 | 1997-11-18 | Eli Lilly And Company | Excitatory amino acid derivatives |
US5952294A (en) | 1996-07-31 | 1999-09-14 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Peptidyl prodrugs and methods of making and using the same |
ZA983930B (en) * | 1997-05-14 | 1999-11-08 | Lilly Co Eli | Excitatory amino acid receptor modulators. |
CN1182105C (zh) * | 1998-01-28 | 2004-12-29 | 大正制药株式会社 | 含氟氨基酸衍生物 |
ATE269293T1 (de) * | 1998-08-31 | 2004-07-15 | Taisho Pharmaceutical Co Ltd | 6-fluoro(3.1.0)hexan-derivate |
US6716452B1 (en) * | 2000-08-22 | 2004-04-06 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
US6313498B1 (en) * | 1999-05-27 | 2001-11-06 | Actrans System Inc. | Flash memory cell with thin floating gate with rounded side wall, and fabrication process |
US6770676B2 (en) * | 2000-06-28 | 2004-08-03 | Taisho Pharmaceutical Co., Ltd. | Dicarboxylic acid derivatives |
WO2002055485A1 (en) * | 2001-01-11 | 2002-07-18 | Eli Lilly And Company | Prodrugs of excitatory amino acids |
NZ526050A (en) * | 2001-01-11 | 2005-03-24 | Lilly Co Eli | Prodrugs of excitatory amino acids |
JP2005505506A (ja) * | 2001-06-12 | 2005-02-24 | イーラン ファーマスーティカルズ、インコーポレイテッド | アルツハイマー病の治療に有用な大環状分子 |
NZ533699A (en) | 2001-12-27 | 2006-05-26 | Taisho Pharmaceutical Co Ltd | 6-fluorobicyclo[3.1.0]hexane derivatives |
US20050192273A1 (en) * | 2002-04-03 | 2005-09-01 | Johnson Bryan G. | Therapy for psychoses combining an atypical antipsychotic and an mglu2/3 receptor agonist |
WO2003084610A1 (en) * | 2002-04-03 | 2003-10-16 | Eli Lilly And Company | Therapy for psychoses combining an atypical antipsychotic and an mglu2/3 receptor agonist |
NZ536459A (en) * | 2002-06-11 | 2008-03-28 | Lilly Co Eli | Prodrugs of excitatory amino acids |
-
2003
- 2003-06-06 NZ NZ536459A patent/NZ536459A/en not_active IP Right Cessation
- 2003-06-06 JP JP2004511287A patent/JP4342437B2/ja not_active Expired - Lifetime
- 2003-06-06 EA EA200500007A patent/EA011231B1/ru not_active IP Right Cessation
- 2003-06-06 PT PT03757266T patent/PT1517915E/pt unknown
- 2003-06-06 PL PL374381A patent/PL221489B1/pl unknown
- 2003-06-06 MX MXPA04012518A patent/MXPA04012518A/es active IP Right Grant
- 2003-06-06 SI SI200331575T patent/SI1517915T1/sl unknown
- 2003-06-06 AU AU2003232146A patent/AU2003232146B2/en not_active Expired
- 2003-06-06 EP EP07122014A patent/EP1897550A3/en not_active Withdrawn
- 2003-06-06 AT AT03757266T patent/ATE421526T1/de active
- 2003-06-06 US US10/516,559 patent/US7371872B2/en not_active Expired - Lifetime
- 2003-06-06 WO PCT/US2003/015405 patent/WO2003104217A2/en active Application Filing
- 2003-06-06 ES ES03757266T patent/ES2319116T3/es not_active Expired - Lifetime
- 2003-06-06 EA EA200801711A patent/EA014979B1/ru not_active IP Right Cessation
- 2003-06-06 EP EP03757266A patent/EP1517915B1/en not_active Expired - Lifetime
- 2003-06-06 DK DK03757266T patent/DK1517915T3/da active
- 2003-06-06 NZ NZ564692A patent/NZ564692A/en not_active IP Right Cessation
- 2003-06-06 DE DE60325968T patent/DE60325968D1/de not_active Expired - Lifetime
- 2003-06-06 CA CA2488167A patent/CA2488167C/en not_active Expired - Lifetime
- 2003-06-06 BR BRPI0311558-5A patent/BR0311558A/pt not_active Application Discontinuation
- 2003-06-06 NZ NZ556437A patent/NZ556437A/en not_active IP Right Cessation
- 2003-06-06 KR KR1020087013701A patent/KR20080058509A/ko not_active Application Discontinuation
- 2003-06-09 MY MYPI20032147A patent/MY146238A/en unknown
- 2003-06-09 PE PE2003000574A patent/PE20040555A1/es not_active Application Discontinuation
- 2003-06-10 AR ARP030102065A patent/AR040257A1/es active IP Right Grant
-
2004
- 2004-11-08 IL IL16510004A patent/IL165100A0/xx not_active IP Right Cessation
- 2004-11-25 ZA ZA2004/09553A patent/ZA200409553B/en unknown
- 2004-12-07 CO CO04122695A patent/CO5631438A2/es not_active Application Discontinuation
- 2004-12-09 CR CR7616A patent/CR7616A/es unknown
- 2004-12-10 HR HRP20041179AA patent/HRP20041179B1/hr not_active IP Right Cessation
-
2005
- 2005-01-10 NO NO20050122A patent/NO331780B1/no not_active IP Right Cessation
- 2005-08-31 HK HK05107648.6A patent/HK1075259A1/xx not_active IP Right Cessation
-
2008
- 2008-02-07 IL IL189355A patent/IL189355A/en not_active IP Right Cessation
- 2008-02-12 NO NO20080765A patent/NO20080765L/no not_active Application Discontinuation
- 2008-02-13 JP JP2008031490A patent/JP2008201779A/ja active Pending
- 2008-03-31 US US12/059,112 patent/US7671082B2/en not_active Expired - Lifetime
- 2008-04-03 EC EC2008005481A patent/ECSP085481A/es unknown
-
2009
- 2009-01-30 HR HR20090058A patent/HRP20090058A2/xx not_active Application Discontinuation
- 2009-04-07 CY CY20091100411T patent/CY1108976T1/el unknown
-
2010
- 2010-01-15 US US12/688,074 patent/US7964632B2/en not_active Expired - Lifetime
-
2011
- 2011-03-10 CR CR20110130A patent/CR20110130A/es not_active Application Discontinuation
- 2011-05-04 US US13/100,642 patent/US8153683B2/en not_active Expired - Fee Related
-
2012
- 2012-03-13 US US13/418,613 patent/US20120172422A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO5631438A2 (es) | Profarmacos de aminoacidos excitadores | |
TR200103337T2 (tr) | Protez inhibitrleri olarak yeni bileçikler ve bileçimler | |
DE60230127D1 (de) | Inhibitoren von integrin alpha-v-beta-6 | |
PE20040636A1 (es) | Ester de 2'-c-metil-3'-o-l-valina de ribofuranosilcitidina | |
UY26721A1 (es) | Nuevos derivados de la fenilglicina | |
HUP0300340A2 (hu) | c-JUN N-terminális kinázok (JNK) és más protein kinázok inhibitorai, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
ES2053609T3 (es) | Derivados de urea inhibidores de lipoxigenasa. | |
HUP0302969A2 (hu) | NPY Y5 antagonisták, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
AR012315A1 (es) | Derivados de ditiolan y el uso de los mismos en la fabricacion de un medicamento. | |
AR088808A2 (es) | Derivados de 2h-piridazin-3-ona, composiciones farmaceuticas que los contienen y un proceso para la preparacion de dichos derivados y el uso de dichos derivados para la preparacion de una composicion farmaceutica | |
CO5611195A2 (es) | Novedosos inhibidores de la gamma secretasa | |
AR025386A1 (es) | Moduladores de los receptores activados del proliferador de peroxisomas | |
AR048567A1 (es) | Derivados de benzoxazinona, su preparacion y composiciones farmaceuticas. | |
CY1107703T1 (el) | Υποκατεστημενες δικετοπιπεραζινες και χρηση αυτων ως ανταγωνιστες οξυτοκινης | |
CY1112066T1 (el) | Νεα παραγωγα ιμιδαζολονων, η παρασκευη τους με τη μορφη φαρμακων, φαρμακευτικες συνθεσεις, χρηση ως αναστολεων πρωτεϊνικων κινασων, κυριως της cdc7 | |
PA8461601A1 (es) | Isoquinolinas | |
AR045793A1 (es) | Compuestos derivados de 3-heterociclil-indol | |
CO5060426A1 (es) | 1-aril-3-imidiopirazoles plaguicidas | |
CO5580782A2 (es) | Antibioticos de glicopeptido-cefalosporina entrecruzados | |
ES2108595B1 (es) | Derivados de la 3(2h)-piridacinona y procedimiento para su preparacion. | |
DE60121587D1 (de) | Zyklische gmp-spezifische phosphodiesteraseinhibitoren | |
ES2151511T3 (es) | Derivado de tiazolina. | |
EA200501164A1 (ru) | Индазоламиды с аналгетической активностью | |
ATE273979T1 (de) | Xanthinderivate, zwischenprodukte und verwendung zur behandlung von osteoporosis | |
ES2541401T3 (es) | Nuevos derivados de isoquinolina disustituidos en 6,7 y su uso |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Application refused |